Skip to main content

BK Virus Infection

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AiCuris
AiCurisGermany - Wuppertal
1 program
1
AIC263029Phase 21 trial
Active Trials
NCT07503561Recruiting24Est. Dec 2027
Symbio Pharmaceuticals
1 program
1
BrincidofovirPhase 2Small Molecule1 trial
Active Trials
NCT05511779Terminated1Est. Apr 2023
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
MAU868PHASE_21 trial
Active Trials
NCT04294472Completed30Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AiCurisAIC263029
Symbio PharmaceuticalsBrincidofovir
Vera TherapeuticsMAU868

Clinical Trials (3)

Total enrollment: 55 patients across 3 trials

NCT07503561AiCurisAIC263029

A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection

Start: Oct 2026Est. completion: Dec 202724 patients
Phase 2Recruiting
NCT05511779Symbio PharmaceuticalsBrincidofovir

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

Start: Oct 2022Est. completion: Apr 20231 patients
Phase 2Terminated
NCT04294472Vera TherapeuticsMAU868

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

Start: Aug 2020Est. completion: Feb 202230 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 55 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.